Research Paper Volume 12, Issue 21 pp 21076—21090

Figure 4. The protective role of miR-136-5p elevation against acute LEDVT is reversed by IL-6 and CRP. The rats used for following assessments were rats treated with miR-136-5p agomir + oe-IL-6, oe-CRP, or oe-NC. (A) The expression levels of miR-136-5p, IL-6, and CRP in vein tissues of rats determined by RT-qPCR. (B) The protein expression of IL-6 and CRP in peripheral blood serum of rats determined by ELISA. (C) The images of acute LEDVT in rats. (D) The length, weight, and the ratio of weight to length of the venous thrombus in response to miR-136-5p agomir + oe-IL-6, oe-CRP, or oe-NC. (E) Pathological changes in vein tissues in rats assessed by HE staining (100 ×). (F) The apoptosis of endothelial cells in the femoral vein in rats assessed by TUNEL assay (200 ×). * p < 0.05 compared with the rats treated with combined treatment of miR-136-5p agomir and oe-NC. Measurement data were expressed as mean ± standard deviation. Data from multiple groups were compared using one-way ANOVA. N = 12 for rats in each group. LEDVT, lower extremity deep vein thrombosis; miR-136-5p, microRNA-136-5p; IL-6, interleukin-6; CRP, C-reactive protein; RT-qPCR, reverse transcription quantitative polymerase chain reaction; ELISA, enzyme linked immunosorbent assay; HE, hematoxylin-eosin; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling; ANOVA, analysis of variance; NC, negative control.